Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis

作者：Wenjia Liu, Yuting Liu, Liqiang Zhang, Liya Li, Wenguang Yang, Jia Li, Wangxiao He · 发表于：Nature Communications · 年份：2025 · DOI：10.1038/s41467-025-59885-x · 被引用次数：19 · 研究领域：Liver physiology and pathology、Tissue Engineering and Regenerative Medicine、Pancreatic function and diabetes

Liver sinusoidal endothelial cells (LSECs) lose their characteristic fenestrations and become capillarized during the progression of liver fibrosis. Mesenchymal stem cell (MSC) transplantation can reverse this capillarization and reduce fibrosis, but MSC therapy has practical limitations that hinder its clinical use. Here, with the help of artificial intelligence (AI), we show that MSCs secrete a microRNA (miR-325-3p) that helps restore LSEC fenestrations (tiny pores) by modulating their cytoskeleton, effectively reversing capillarization. We further develop a spherical nucleic acid (SNA) nanoparticle carrying miR-325-3p as an alternative to MSC therapy. This SNA specifically enters fibrotic LSECs via the scavenger receptor A (Scara). In three mouse models of liver fibrosis, the SNA treatment restores LSEC fenestrations, reverses capillarization, and significantly reduces fibrosis without adverse effects. Our findings highlight the potential of SNA-based therapy for liver fibrosis, paving the way for targeted nucleic acid treatments directed at LSECs and offering hope for patients. RNAi therapies have potential to treat a range of diseases including liver fibrosis. Here, the authors report on the delivery of miR-325-3p in nucleic acid spheres, which can enter the liver sinusoidal endothelial cells, reversing their capillarisation, treating liver fibrosis in mice.